Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack

Cephalalgia

Volumn 25, Issue 3, 2005, Pages 179-183

  Juhasz, G ^a   Zsombok, T ^a   Jakab, B ^b   Nemeth, J ^b   Szolcsanyi, J ^b   Bagdy, Gyorgy ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Calcitonin gene related peptide (CGRP); Headache; Migraine; Nitroglycerin; Sumatriptan

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; GLYCERYL TRINITRATE; SUMATRIPTAN; SUMATRIPTAN SUCCINATE;

ADULT; AEROSOL; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; MIGRAINE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

BIOLOGICAL MARKERS; CALCITONIN GENE-RELATED PEPTIDE; FEMALE; HUMANS; MIDDLE AGED; MIGRAINE WITHOUT AURA; NITROGLYCERIN; SEVERITY OF ILLNESS INDEX; SUMATRIPTAN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 14644431824     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2005.00836.x     Document Type: Article

References (32)

1. Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilation: reversal by sumatriptan. Lancet 1991; 338:13-7.
2. Williamson DJ, Hargreaves RJ, Hill RG, Shephard SL. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anesthetized rat - intravital microscope studies. Cephalalgia 1997; 17:525-31.
3. Fullerton T, Komorowski-Swiatek D, Forrest A, Gengo FM. The pharmacodynamics of sumatriptan in nitroglycerin-induced headache. J Clin Pharmacol 1999; 39:17-29.
4. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. Eur J Pharmacol 2002; 452:223-8.
5. Buzzi MG, Carter WB, Shimizu T, Heath H, 3rd Moskowitz MA. Dihydergotamine and sumatriptan attenuate concentrations of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of trigeminal ganglion. Neuropharmacology 1991; 30:1193-200.
6. Goadsby PJ, Edvinsson L. The trigemino-vascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33:48-56.
7. Knyihar-Csillik E, Tajti J, Samsam M, Sáry G, Slezak S, Vecsei L. Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. J Neurosci Res 1997; 48:449-64.
8. Limmroth V, Katsarava Z, Liedert B, Guehring H, Schmitz K, Diener HC, et al. An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. Pain 2001; 92:101-6.
9. 1B/1D agonists) in acute migraine treatment, a meta-analysis of 53 trials. Lancet 2001; 358:1668-75.
10. 1D receptors in human trigeminal ganglion: co-localisation with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res 2001; 909:112-20.
11. Edvinsson L, Goadsby PJ. Neuropeptides in migraine and cluster headache. Cephalalgia 1994; 14:320-7.
12. Edvinsson L, Goadsby PJ. Neuropeptides in the cerebral circulation: relevance to headache. Cephalalgia 1995; 15:272-6.
13. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl 7:1-96.
14. American Psychiatric Association. Diagnostic and Statistical Manual-IV. Washington, D.C.: American Psychiatric Press, Inc, 1994.
15. Nemeth J, Oroszi G, Jakab B, Magyarlaki M, Szilvassy Z, Roth E, et al. 125I- labeling and purification of peptide hormones and bovine serum albumin. J Radioanal Nucl Chem 2002; 251:129-33.
16. Nemeth J, Gorcs T, Helyes Z, Oroszi G, Kocsy T, Pinter E, et al. Development of a new sensitive CGRP radioimmunoassay for neuropharmacological research. Neurobiology 1998; 6:473-5.
17. Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport 1993; 4:1027-30.
18. Bellantonio P, Micieli G, Buzzi MG, Marcheselli S, Castellano AE, Rossi F, et al. Heamodynamic correlates of early and deleyed responses to sublingual administration of isosorbide dinitrate in migraine patients: a transcranial Doppler study. Cephalalgia 1997; 17:183-7.
19. Thomsen LL, Olesen J. Nitric oxide theory of migraine. Clin Neurosci 1998; 5:28-33.
20. Tassorelli C, Joseph SA, Buzzi MG, Nappi G. The effects on the central nervous system of nitroglycerin - putative mechanisms and mediators. Prog Neurobiol 1999; 57:607-24.
21. Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003; 106:461-70.
22. Iversen HK, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia 1996; 16:412-8.
23. Edvinsson L. Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications. CNS Drugs 2001; 15:745-53.
24. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol 2002; 137:62-8.
25. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002; 22:54-61.
26. Pardutz A, Multon S, Malgrange B, Parducz A, Vecsei L, Schoenen J. Effect of systemic nitroglycerin on CGRP and 5-HT afferents to rat caudal spinal trigeminal nucleus and its modulation by estrogen. Eur J Neurosci 2002; 15:1803-9.
27. Durham PL, Russo AF. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drugs. J Neurosci 1999; 19:3423-9.
28. Knight YE, Edvinsson L, Goadsby PJ. Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat. a comparison of avatriptan and CP122,288. Neuropeptides 1999; 33:41-6.
29. Knyihar-Csillik E, Tajti J, Csillik AE, Chadaide Z, Mihaly A, Vecsei L. Effects of eletriptan on the peptidergic innervation of cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci 2000; 12:3991-4002.
30. Knight YE, Edvinsson L, Goadsby PJ. 4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT (1B/1D) receptor agonist activity? Neuropharmacology 2001; 40:520-5.
31. Knyihar-Csillik E, Tajti J, Chadaide Z, Csillik B, Vecsei L. Functional immunochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine. Microsc Res Tech 2001; 53:193-211.
32. Stepien A, Jagustyn P, Trafny A, Widerkiewicz K. Effect of rizatriptan on CGRP level in migraine. Cephalalgia 2003; 23:738.